Breakthrough T1D's Multifaceted Approach to Type 1 Diabetes

The organization formerly known as JDRF is pursuing cure research alongside practical improvements to daily diabetes management. Here's how they're working across multiple fronts to transform the field.

Video report — unverified, pending corroboration

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

Breakthrough T1D funds research into disease-modifying therapies, cell replacement approaches, and immune therapies designed to stop the autoimmune attack underlying Type 1 diabetes
The organization supports both cure-focused work and immediate quality-of-life improvements, including advances in continuous glucose monitoring technology and artificial pancreas systems
Decades of investment have contributed to progress across multiple research areas, from basic science to practical tools for living with diabetes

A Broad Research Portfolio

Breakthrough T1D, which rebranded from its longtime name JDRF, frames its mission around three interconnected goals: curing Type 1 diabetes, preventing it, and improving treatments for those living with it today. Rather than betting everything on a single approach, the organization funds research across multiple scientific pathways.

These include disease-modifying therapies that could alter the disease's course, cell replacement and regeneration strategies that aim to restore insulin-producing function, and immune therapies designed to stop the autoimmune process that causes Type 1 diabetes in the first place.

Beyond the Lab: Real-World Impact

Breakthrough T1D's work extends well beyond cure-focused research. The organization has played an instrumental role in advancing diabetes technology that directly affects people's daily lives. This includes helping drive early adoption of continuous glucose monitors—devices that have become essential tools for many in the Type 1 community.

The organization has also funded pivotal studies supporting artificial pancreas (AID) systems, automated insulin delivery technologies that help reduce the daily burden of diabetes management. This dual focus—combining long-term cure research with near-term improvements in care—shapes how Breakthrough allocates its resources and directs its scientific agenda.

Decades of Progress

Over many years, Breakthrough T1D's investment strategy has contributed to measurable advances across the diabetes research landscape. By supporting work on multiple fronts simultaneously, the organization has helped accelerate progress in areas that might otherwise advance more slowly, while also ensuring that people living with Type 1 diabetes today benefit from improved tools and treatments.

Evidence label

Origin: YouTube / Diabetech (Video report). Evidence: Video report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.